Articles related to SCHIZOPHRENIA

A narrative review and accompanying expert commentary outlined diagnostic features distinguishing substance-induced psychosis from primary psychotic disorders amid rising cannabis and stimulant exposure.

The Tardive Dyskinesia Impact Scale showed high discrimination and precision across physical function and socioemotional domains in pooled data from 388 patients in the KINECT 3 and KINECT 4 valbenazine trials.

A J Clin Psychiatry commentary proposes a risk-benefit matrix favoring empiric catatonia treatment when diagnostic uncertainty exists, citing the syndrome’s high morbidity and the effectiveness of available interventions.

The FDA approved a supplemental NDA adding randomized withdrawal trial data to the lumateperone label, supporting its role in long-term maintenance and relapse prevention in adults with schizophrenia.

A network meta-analysis of 24 antipsychotics across 78,193 patients with schizophrenia identified clozapine, amisulpride, olanzapine, and risperidone as most effective, with small-to-medium efficacy differences and notable variation in tolerability profiles.

The new chemical entity is an atypical antipsychotic and the active metabolite of iloperidone (Fanapt). Its ability to cross the blood-brain barrier likely contributes to iloperidone’s clinical effects.